Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≤ 75 years.~* ECOG ≤ 3.~* Morphologic Diagnosis of LPA (FAB M3 or variant M3). Those cases without typical morphology but with PML-RARα reordering also must be including.~* Genetic Diagnosis: t (15; 17) demonstrated by cariotipo conventional, FISH, PML-RARα reordering detected by RT-PCR or a pattern microspeckled demonstrated with antibody anti-PML (positive PGM3). Obvious, it will be had the result of these tests once initiated the treatment on the basis of a suspicion diagnoses morphologic~Exclusion Criteria:~* Age \>75 years (the treatment with this protocol can be considered individually)~* Absence of PML-Rare reordering.~* To have received previously some type of treatment for LPA, including chemotherapy or retinoides. The previous treatment with corticoids, hidroxiurea or leucoaféresis is not reason for exclusion.~* To have received chemotherapy or x-ray for the treatment of a disease vitiates previous.~* Associate Neoplasia.~* Serious psychiatric Disease.~* Seropositividad for VIH.~* Contraindication to receive intensive chemotherapy, specially antraciclinas.~* Sérica Creatinina ≥ 2,5 mg/dL (≥ 250 μmol/l).~* Bilirrubina, fosfatasa alkaline, or GOT \> 3 times the normal limit~* Test of positive pregnancy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).